Table 4. The Association of Clinicopathological Data and COX Immunostaining With Survival.
| Clinical data | Multivariate analysis |
|
|---|---|---|
| Hazard ratio (95% CI) | p | |
| Age | ||
| ≤ 60 years | 2.29 | 0.013 |
| > 60 years | (1.19 – 4.39) | |
| Residual disease | ||
| no residual | 2.93 | 0.05 |
| residual | (1.00 – 8.62) | |
| Histology | ||
| Mucinous | 3.68 | 0.004 |
| Non-mucinous | (1.51 – 8.94) | |
| Tumor grade | ||
| Grade 1-2 | 2.00 | 0.059 |
| Grade 3 | (0.98 – 4.10) | |
| FIGO stage | ||
| Stage 1-2 | 4.17 | 0.018 |
| Stage 3-4 | (1.27 – 13.70) | |
| COX -1 and COX-2 expression | ||
| Others group | 5.90 | < 0.0001 |
| High COX-1 and low COX-2 | (2.38 – 14.59) | |